Chemopreventive properties of curcumin analogues, hexagamavunone-0 and gamavutone-0, in rat colorectal cancer model
Purpose: To examine the chemopreventive activity of curcumin analogues, hexagamavunone-0 (HGV- 0) and gamavutone-0 (GVT-0), compared to curcumin in a colorectal cancer model in Wistar rats.
Methods: Rats (n = 25) were assigned to one of five groups (n = 5 in each group). Colorectal cancer was induced in the control group with subcutaneous injection of 1,2-dimethylhydrazine (DMH) 60 mg/kg once a week for 15 weeks. In addition to DMH injection, treatment groups were treated with curcumin (20, 40, or 80 mg/kg), gamavutone-0 (GVT-0; 20, 40, or 80 mg/kg), and hexagamavunone (HGV-0; 20, 40, or 80 mg/kg) orally twice a week for 15 weeks. The number and volume of nodules in the colorectal area were observed after laparatomy. Histopathological analysis was performed using H & E staining and immunohistochemistry with antibodies against adenomatous polyposis coli (APC) and cyclooxygenase 2 (COX-2).
Results: All treatments reduced colorectal nodule volume, but only HGV-0 significantly decreased the numbers of nodules compared to DMH controls (p < 0.05). The reduction was 96.1 % with 40 mg/kg HGV-0. Mutated APC expression was inhibited by curcumin, GVT-0, and HGV-0 at a dose of 40 mg/kg, whereas COX-2 expression was mostly inhibited by HGV-0 (20 and 40 mg/kg) and curcumin to a lesser extent, but not inhibited by GVT-0 treatment in rat colorectal cancer.
Conclusion: HGV-0 showed superior chemoprevention compared to GVT-0 and curcumin. HGV-0 at a dose of 40 mg/kg significantly reduced the number and volume of colorectal nodules. The mechanism of chemoprevention of HGV-0 is related to its inhibition of APC mutation and COX-2 expression.
Keywords: Curcumin, Gamavutone-0, Hexagamavunone-0, Colorectal cancer, Adenomatous polyposis coli, Cyclooxygenase-2
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.